LinkedIn image ad examples

Adding quantitative brain volumetrics doesn't have to mean rebuilding your imaging workflow. Neuroreader® supports web-based access and integrated PACS workflows. Compatible brain MRI is transferred for automated analysis, brain structures are segmented and quantified, and the resulting quantitative information is returned for physician review. For higher-volume environments, Brainreader's Mediation Server enables direct communication between Neuroreader® and PACS. See how Neuroreader® can fit into your Federal healthcare imaging environment.

Go beyond visual assessment. Neuroreader® automatically analyzes compatible brain MRI to provide quantitative volumetric information for physician review. 83 brain volumes. Less than 10 minutes. Compatible 3D T1 MRI. Give radiologists, neurologists, and other clinical teams objective measurements they can review alongside the imaging study and broader clinical picture.

👉 Aan de slag als (Senior) Financieel Medewerker bij ETB-BISLIFE? Zorg voor een nauwkeurige financiële en salarisadministratie en draag bij aan de periodieke controles en procesverbetering. Heb je relevante ervaring? Solliciteer direct.

Your pathologists take leave. Your cases still get read.

Who is covering your pathology workload this holiday season?

A team I worked with was building an ML model on a combination of de-identified datasets. But they'd lost before they even started. They started with 600 columns. Before anyone could figure out which ones actually mattered for the predictions, 40% of them were dropped in a second de-identification pass. Combine two de-identified datasets and you almost always trigger more redactions. The part that struck me was that they didn't mourn (for lack of better word) the loss of those features. Sure, if you asked them if they'd rather have those columns back and... of course they'd say yes. But there was nothing they could do about it so they just accepted that 40% of the analytical value in that dataset was vaporized. It's the classic: ask a fish "how's the water?" and it'll say "what's water?". So common and ubiquitous and expected that its nearly imperceptible. What is actually sitting in that 40%? A signal nobody will ever find…a better prediction? For a cure? A new intervention? We'll never know! The model came out fine, fwiw. Building a good model isn't and won't ever be the hard part. It's the never-to-be-seen upside that should haunt your dreams (we all dream about redaction-induced data loss, right?). Thankfully, this is changing in no small part due to advances in AI. There are now ways to keep the privacy compliance and keep the value - that's what we're building at Subsalt. So. Keep the columns. All six hundred of them. Sit with the long tail a while - they have the best stories. Order the granular codes. Order the dates, too. Let the data tell you where it's been. Because the good stuff - the marrow, the AUC, F1 score - lives in the unredacted version of everything. Has anyone at your org ever estimated what the cost of what de-identification deletes? Opportunity cost is too infrequently considered imo. #HealthcareAI #ResponsibleAI #HealthData #MachineLearning #DataStrategy

1 in 10 health claims gets rejected (IRDAI, FY24). That's revenue left waiting. eClinicalWorks HMIS connects TPA approvals, documentation, and settlements into one workflow. Connect with our team eclinicalworks.in. [eClinicalWorks, eClinical Works, HMIS, TPA management, TPA approval, Digital healthcare, Healthcare Automation, Healthcare, Hospital Revenue Cycle management] #eClinicalWorksIndia #DigitalHealthIndia #HealthcareInnovation #HMIS #HospitalManagementSoftware

Erste Hilfe am Arbeitsplatz – für alle praktikabel, ganz ohne Vorkenntnisse. Einfach anzuwenden und leicht nachzufüllen.

Partner with InReach to source top-tier surgeons and medical professionals to provide robust surgical solutions to your community, in your community.

Partner with InReach to bring physical, occupational, and speech therapy services to your community, in your community.

Erste‑Hilfe‑Lösungen für den Arbeitsplatz – einfach anzuwenden, ohne Vorkenntnisse und leicht nachzufüllen.

Billing headaches? Our AI PT EMR keeps claims compliant, tracks revenue in real time, and helps your team get paid faster. See it in a free demo.

What does pharma content production really cost? For one global life sciences organisation, the answer was significant. Their internal business-case model compared a traditional digital factory approach with self-service content authoring across 10,000+ marketing and approved emails. The model identified: €1.47M in potential production cost difference 48,000+ production days potentially saved But the most interesting part isn’t the headline numbers. It’s why the economics change. The business case looks at what happens when teams move beyond simply outsourcing production and redesign the operating model around reuse, templates, governance and self-service authoring. We’ve turned the full analysis into a 13-page Executive Business Case, including: ➛ the cost model, broken down line by line ➛ the time-to-market model ➛ the mechanisms behind the projected impact ➛ an 8-point framework to benchmark your own content operation ➛ five questions to help you start the business-case conversation internally The organisation has been anonymised for confidentiality, and all figures are based on its own internal calculations and projections rather than independently audited realised savings. Start building the business case for your own content transformation now https://lnkd.in/dsFgUGSe #PharmaMarketing #ContentExcellence #PharmaContent #ContentOperations #DigitalTransformation

𝗜𝗻𝘃𝗲𝘀𝘁𝗲𝗲𝗿 𝗶𝗻 𝗱𝗲 𝗴𝗲𝘇𝗼𝗻𝗱𝗵𝗲𝗶𝗱 𝘃𝗮𝗻 𝗺𝗼𝗿𝗴𝗲𝗻 𝗺𝗲𝘁 𝗣𝘂𝗹𝘀𝗲𝟰𝗮𝗹𝗹.📈 Met een jaarlijkse rente van 8% en een looptijd van 4 jaar, biedt deze investering een mooie combinatie van rendement en maatschappelijke impact. Investeren kan al vanaf € 1.000. Wilt u meer informatie ontvangen? Vraag vrijblijvend de brochure aan. Beleggen brengt risico's met zich mee. U kunt uw inleg verliezen. Lees het Basisprospectus op https://lnkd.in/eR5HJdqY voordat u een beleggingsbeslissing neemt.

𝗪𝗲 𝗸𝘂𝗻𝗻𝗲𝗻 𝗵𝗲𝘁 𝗵𝗲𝗲𝗹 𝘀𝗶𝗺𝗽𝗲𝗹 𝗺𝗮𝗸𝗲𝗻. Met een investering in Pulse4all helpt u om AED’s grootschalig beschikbaar te maken in Europa. Dat is mooi. U draagt bij aan een veiligere omgeving én ontvangt een vaste rente van 8% per jaar, met een looptijd van 4 jaar. Dat is natuurlijk nog mooier. Instappen kan vanaf € 1.000. Ontvang de brochure en bekijk hoe deze investering werkt. Beleggen brengt risico's met zich mee. U kunt uw inleg verliezen. Lees het Basisprospectus op https://lnkd.in/eR5HJdqY voordat u een beleggingsbeslissing neemt.

Patholytix is excited to be exhibiting at Booth 20 during the 16th World Clinical Biomarkers & Companion Diagnostics Summit. taking place October 5-8 in Boston, MA. Visit our booth to learn how Patholytix combines expert pathology, advanced laboratory services, a flexible Image Management System (IMS), and AI-powered analysis to support pharmaceutical companies from early translational research through large, global clinical trials. Whether you're developing companion diagnostics, validating digital biomarkers, or managing complex research programs, Patholytix helps transform tissue data into high-quality, decision-ready insights. Meet the team: Georgia Cresswell Pierre Moulin Colin Doolan Don't miss our speaking session during the conference, where Pierre Moulin will share practical insights into AI, computational pathology, and digital pathology in pharmaceutical research. "Pathology Reimagined: Expert Insight and Intelligent Tools for CDx and Biomarker Trials" - Pierre Moulin Book a meeting with our team: https://lnkd.in/eEddr3Ys We look forward to seeing you in Boston! #Biomarkers #ClinicalTrials #DigitalPathology #CompanionDiagnostics #Patholytix

Als dramatherapeut krijg je bij Cirya de ruimte om echt een behandeling te bieden. Niet maximaal 5 sessies, maar als gelijkwaardig onderdeel van de behandeling. Werk jij graag met kinderen, jeugdigen en volwassenen en past dit bij jou? Kijk dan snel verder.

Money talks. The problem is it whispers. Months before anyone admits it out loud, capital is already leaning toward certain corners of health tech. By the time it's obvious, the good terms are gone and everyone's chasing the same conversation. Orbit hears it early. Not a prediction. A signal, tracked in real time, so you're never the last to know where the capital is heading. And that is just a small example of what Orbit can do.

Read Dental Director Dr. Neil Parikh’s DentistryIQ article: Closing the dental care gap - how FQHCs expand preventive care access. https://lnkd.in/eTK755yC

Are rebates losing their place as the primary measure of PBM value? The pharmacy benefits landscape is changing rapidly. The Inflation Reduction Act, biosimilars and evolving manufacturer pricing are reshaping how employers evaluate pharmacy benefit strategies. As rebate guarantees become less predictable, organizations need to look beyond rebates and focus on total net cost. Join us for our upcoming webinar: 📅 The Future of PBM Contracting: Is the High-Rebate Model Coming to an End? Date: Thursday, October 15, 2026 at 1:00 PM ET Featuring: Phil Bruns, Sales Director, HarmonyRx, and Anu Dhamecha, PharmD, The MJ Companies. Reserve Your Spot Today: https://lnkd.in/eTtj_2GR/?utm_campaign=Boost_Post_Engagement_Sep29,2026&utm_source=linkedin&utm_medium=paid&utm_id=1215205234&hsa_acc=519040050&hsa_cam=1215205234&hsa_grp=900892044&hsa_ad=1578706404&hsa_net=linkedin&hsa_ver=3 Our experts will discuss: ✔ How the Inflation Reduction Act is changing pharmacy pricing ✔ High-WAC vs. Low-WAC contracting models ✔ Why rebate guarantees are becoming more challenging ✔ How biosimilars are transforming the marketplace ✔ What employers, brokers and consultants should be asking their PBM ✔ Why total net cost is becoming the new benchmark for value 📘 Exclusive Bonus: Everyone who registers will receive our new white paper, The Future of PBM Contracting: Is the High-Rebate Model Coming to an End? This in-depth resource expands on the webinar with additional market insights, practical guidance and strategies you can use long after the session ends. Whether you're reviewing your current PBM contract or preparing for future renewals, this webinar will help you better understand the forces shaping pharmacy benefits today. #PharmacyBenefits #PBM #HealthcareBenefits #EmployeeBenefits #SelfFunded #Biosimilars #InflationReductionAct #HealthcareCosts #BenefitsConsulting #HarmonyRx

Medical Affairs is evolving. Expectations are rising. If your engagement model needs to change, now is the time to explore what a different approach can deliver. Discover EPIKAST at epikast.com.

Unser Geschäftsführer Thomas Stadler war beim OTC-Summit von Pharma Deutschland in Berlin Teil der abschließenden Diskussionsrunde zur Zukunft der Selbstmedikation. Dabei machte er deutlich: Unser Gesundheitssystem stößt bereits heute an seine Belastungsgrenzen. Um es langfristig zu entlasten und finanzierbar zu halten, sollten die Möglichkeiten der Selbstmedikation stärker genutzt werden. Für Thomas Stadler gehört dazu aber auch die richtige Unterstützung. Er betonte die Bedeutung einer engen Zusammenarbeit der Heilberufe und die wichtige Rolle der Apotheken als niedrigschwellige und persönliche Anlaufstellen für Patientinnen und Patienten. Ein Thema, das uns bei HERMES ARZNEIMITTEL natürlich besonders beschäftigt und das wir auch in Zukunft aktiv mitgestalten möchten. 💚 📸 ©️Christina Czybik

AI can generate a million protein designs. The bottleneck has always been measuring them. At Onava AI, Sharrol Bachas builds a closed loop between in-silico design and the wet lab: where models propose, assays measure, and the data flows straight back into training. FIDA has become a core enabler: high-throughput, in-solution binding and functional data that models can actually learn from. See how the design–measure–learn loop works in practice. ▶ Watch the on-demand webinar:

What happens when a lab that already owns SPR, ITC, DLS, AUC and MST adds one more instrument? It often ends up being their go-to solution. Why? Timothy Sharpe (University of Basel) shares a year of real, difficult core-facility cases and where FIDA delivered accuracy and a wealth of data that can change the way efficiency can be defined in core facility workflows. Explore the application cases. ▶ Watch "Solving Difficult Cases at a Core Facility":